Adverse effects of hypertensive agents
92 results
1 - 92
Hydralazine for essential hypertension
Adverse effects of antineoplastic agents - Drug treatment for hypertension
- Methyldopa for primary hypertension: Cochrane systematic review
- Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials: Cochrane systematic review
- Long-term adverse effects of antineoplastic agents
- Elevated blood pressure in pregnancy (gestational hypertension, pre-eclampsia)
- Blood pressure‐lowering efficacy of reserpine for primary hypertension
- Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
- Pharmacotherapy for hyperuricaemia in hypertensive patients
- Pharmacological interventions for hypertension in children
- Diuretics as second-line therapy for primary hypertension
Riociguat marginally effective for pulmonary hypertension- Blood pressure lowering efficacy of diuretics as second‐line therapy for primary hypertension
- Pharmacotherapy for hypertension in the elderly
- Renin inhibitors versus angiotensin receptor blockers for primary hypertension
- Spironolactone most effective add-on for patients with resistant hypertension (PATHWAY-2)
- Eplerenone for hypertension
- Guanylate cyclase stimulators for pulmonary hypertension
- Carbetocin for preventing postpartum haemorrhage: Cochrane systematic review
- Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants
- Choice of prophylactic medication for atrial fibrillation - Image
- Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
- Drugs for rapid treatment of very high blood pressure during pregnancy
- Long-term pharmacotherapy for obesity and overweight: Cochrane systematic review
- Higher blood pressure targets for hypertension in older adults
- Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension: Cochrane systematic review
- Blood pressure control for diabetic retinopathy
- Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
- Interventions for idiopathic steroid‐resistant nephrotic syndrome in children
- Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients
- Antihypertensive agents for preventing diabetic kidney disease
- Erythropoiesis‐stimulating agents for preventing acute kidney injury
- Drugs for treatment of very high blood pressure during pregnancy
- Interventions for minimal change disease in adults with nephrotic syndrome
- Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension
- Prophylactic ergometrine‐oxytocin versus oxytocin for the third stage of labour
- First‐line diuretics versus other classes of antihypertensive drugs for hypertension
- Thiazide diuretics and the risk of hip fracture: Cochrane systematic review
- Vitamins C and E ineffective for PIH
- Sedatives for opioid withdrawal in newborn infants
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer
- AHA/ACC guideline for the primary prevention of stroke
- Beta-adrenergic blocking agents and intermittent claudication
- Interventions for preventing the progression of autosomal dominant polycystic kidney disease
- Prevention of atrial fibrillation
- Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
- Intravenous versus inhalational techniques for rapid emergence from anaesthesia in patients undergoing brain tumour surgery
- Pharmacological interventions for asymptomatic carotid stenosis
- Hydralazine in infants with persistent hypoxemic respiratory failure: Cochrane systematic review
- Systemic lupus erythematosus (SLE)
- Antiplatelet agents for preventing pre-eclampsia
- Urinary incontinence in women
- Chinese herbal medicines for hypertriglyceridaemia: Cochrane systematic review
- Cardioselective beta‐blockers for reversible airway disease
- Hypertonic saline versus other intracranial pressure–lowering agents for people with acute traumatic brain injury
- Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients
- Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis
- Antiplatelet agents for the treatment of adults with COVID‐19
- Curcumin for maintenance of remission in ulcerative colitis
- Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
- Effect of cyclosporine on blood pressure: Cochrane systematic review
- Lower limb ischaemia
- Rofecoxib for osteoarthritis
- Statins for the primary prevention of cardiovascular disease
- Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis
- Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta‐analysis
- Acute heart failure and pulmonary oedema
- Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants
- Thrombolytic therapy for pulmonary embolism
- Assessment and treatment of a patient with bleeding diathesis
- ACE inhibitors and angiotensin receptor blockers for progression of non-diabetic renal disease
- Oral aspirin for treating venous leg ulcers
- Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
- Aqueous shunts with mitomycin C versus aqueous shunts alone for glaucoma
- Dietary supplementation with myo‐inositol in women during pregnancy for treating gestational diabetes
- Vascular‐endothelial‐growth‐factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
- Corticosteroid therapy for nephrotic syndrome in children
- Use of medication during pregnancy
- Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis
- Chronic heart failure
- Treatment of chronic renal failure